New European Commission Study To Review Experience With Human Drug Authorization Procedures
Executive Summary
The European Commission is deciding on the terms of reference of an external study, to be completed in 2018, in order to comply with its legal obligation of publishing a general report every 10 years on the experience acquired with various EU marketing authorization procedures for human drugs.
You may also be interested in...
A decade in charge of the EMA
European Medicines Agency executive director Thomas Lönngren talks to Maureen Kenny about transparency, legacy and the lack of a successor in the run-up to his departure from the agency.
Organisational changes critical to EMA's sustainability, says new report
While the European Medicines Agency has proven effective in protecting human and animal health in the European region, the whole medicines authorisation system "is progressively attaining its maximum capacity", says a new report published by the European Commission1,2. Thus, there is an urgent need for the agency to appropriately alter its organisation to ensure its sustainability in the face of novel challenges.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.